The patient's body needs the drug just to feel normal. That's not weakness.
In Nigeria, where sickle cell disease afflicts millions with relentless, body-breaking pain, a quieter crisis has taken root alongside the illness itself: the medications designed to offer relief are, for a growing number of patients, becoming a source of new suffering. Medical experts are raising alarms about opioid addiction rates among sickle cell patients reaching 11.7 percent in some regions — figures that rival or exceed those of the broader chronic pain population. This is not a story of moral failure, but of a healthcare system navigating the impossible tension between alleviating agony and preventing dependency, in a context where oversight is thin and alternatives remain out of reach for many.
- Sickle cell patients in Nigeria face vaso-occlusive pain crises so severe that opioids are not a choice but a medical necessity — yet those same drugs are fueling addiction rates as high as 11.7 percent in some regions.
- The line between physiological dependence and psychological addiction is collapsing in real time: patients have secretly consumed ward morphine supplies, fabricated stories to obtain pentazocine, and sold possessions to feed cravings.
- Pentazocine, the most commonly abused opioid in this population, carries compounding dangers — euphoria, injection-site infections, and pathways to HIV and hepatitis through shared needles.
- Healthcare professionals are divided on how to respond, caught between the ethical imperative to treat severe pain and the absence of robust prescription monitoring, specialist training, and psychological support infrastructure.
- Alternatives like hydroxyurea and the herbal-derived Ciklavit offer some patients a way to reduce opioid reliance, but access and awareness remain deeply uneven across Nigeria.
- Experts are calling for a coordinated response — evidence-based prescribing protocols, family education, institutional monitoring, and preventive care — to break the cycle before it deepens further.
In Port Harcourt, a pharmacist named Chinedum recalls a sickle cell patient who arrived repeatedly with increasingly elaborate stories, each crafted to obtain pentazocine without a prescription. When refused, she grew angry and tearful, insisting he could not understand what it meant to live in a body that regularly turned against itself. What he witnessed was not cruelty, but the visible edge of a crisis now drawing alarm from medical professionals across Nigeria: opioid addiction among sickle cell disease patients is rising at a rate that may exceed that of the general chronic pain population.
Sickle cell disease is a genetic blood disorder in which red blood cells become rigid and sickle-shaped, jamming in narrow vessels and cutting off oxygen — triggering vaso-occlusive crises of severe pain lasting hours or days. Sub-Saharan Africa bears nearly 80 percent of the global burden. Because the pain is relentless and recurring, treatment escalates from over-the-counter options to prescription opioids like morphine, oxycodone, and fentanyl. Studies in northwest Nigeria have found addiction rates of 11.7 percent among SCD patients, compared to roughly 10 percent in the United States — suggesting the risk in Nigeria may be even higher than in the general chronic pain population.
The distinction between physiological dependence and psychological addiction has become a flashpoint. Some experts argue that regular opioid use for severe, recurring pain is medically expected and not equivalent to addiction. Others point to documented cases that blur the line sharply: a patient who secretly drank morphine from a ward refrigerator and collapsed; another who fabricated stories to obtain pentazocine. Pentazocine is particularly dangerous — it triggers euphoria and powerful cravings, is typically injected, and exposes users to infection and blood-borne diseases through shared needles.
Alternative approaches exist. Hydroxyurea can prevent pain crises, and Ciklavit, derived from the herb Cajanus cajan, offers a multivitamin-based option that some patients report improves their overall health and reduces reliance on painkillers. But access remains uneven. Pharmacist and sickle cell advocate Perpetua Nnabuenyi argues that preventing addiction requires effort at every level — patients adhering to prescribed doses, families watching for early signs of dependence, and institutions implementing prescription monitoring, professional training, and psychological support.
The path forward is not to deny patients the relief they genuinely need, but to build systems that deliver it safely. Without such systems, the woman at Chinedum's counter — caught between unbearable pain and the risk of addiction to the only medicine available — will not be the last.
In Port Harcourt, a pharmacist named Chinedum remembers a sickle cell patient who would arrive at his counter with increasingly elaborate stories, each one designed to extract a prescription for pentazocine—an opioid painkiller. She would grow angry when refused, sometimes tearful, insisting that he simply did not understand what it felt like to live inside a body that regularly turned against itself. He refused to dispense the drug without a doctor's order, even as she accused him of wanting her to suffer. What Chinedum witnessed was not cruelty on her part, but the visible edge of a larger crisis: medical experts across Nigeria are now warning that opioid addiction among sickle cell disease patients is rising at an alarming rate, driven by the very medications meant to relieve their suffering.
Sickle cell disease is a genetic blood disorder caused by a mutation in the hemoglobin gene. The mutation causes red blood cells to become rigid and sickle-shaped, unable to move freely through narrow blood vessels. They jam up, blocking oxygen flow and triggering what doctors call vaso-occlusive crises—episodes of severe pain that can last hours or days. The World Health Organisation estimates that 7.74 million people worldwide live with the disease, with sub-Saharan Africa accounting for nearly 80 percent of cases. In 2021 alone, the condition killed 81,100 children under five, though the actual death toll is believed to be eleven times higher when accounting for underreporting. Beyond the pain crises, patients contend with anemia, bone and muscle aches, joint swelling, fatigue, and the yellowing of eyes and skin.
Because pain is relentless and recurring, treatment typically begins with over-the-counter options like acetaminophen or ibuprofen for mild episodes. But moderate to severe crises demand stronger medicine: prescription opioids such as morphine, oxycodone, or fentanyl. The problem is that opioids carry their own danger. In the United States, about 10 percent of sickle cell patients develop opioid use disorder. But a study in northwest Nigeria found rates of 11.7 percent, and another in Uganda reported between 5.3 and 8.5 percent. These numbers suggest that in Nigeria, the addiction risk may actually exceed that of the general chronic pain population.
The distinction between legitimate dependence and addiction has become a flashpoint among medical professionals. Some experts argue that when a patient requires opioids regularly to manage severe, recurring pain, physiological dependence is not only expected but necessary—it is not the same as psychological addiction. When pain goes undertreated, patients may seek prescriptions from multiple doctors or push assertively at pharmacy counters, behaviors often labeled as drug-seeking. But some researchers call this "pseudoaddiction," a desperate scramble for adequate relief rather than true addiction. Yet the line blurs quickly. A hospital source described an SCD patient who, after receiving a dose of morphine, secretly drank more from the ward refrigerator and collapsed. Another patient would arrive with fabricated stories to obtain pentazocine. These are not abstract cases.
Pentazocine, one of the most commonly abused opioids among sickle cell patients, presents particular risks. It binds to opioid receptors in the brain to block pain signals, but it also triggers euphoria, restlessness, and agitation. Patients can develop such powerful cravings that they will sell possessions to buy more. Because pentazocine is typically injected—intravenously, subcutaneously, or intramuscularly—repeated use creates opportunities for infection at injection sites. Shared needles expose users to blood-borne diseases like HIV and hepatitis. The drug can also push patients toward other opioids, deepening the spiral.
Pharmacist James Uche explained that NSAIDs, another common painkiller choice, carry their own complications. Repeated use can damage the stomach lining and cause peptic ulcers. Long-term use can injure the kidneys, especially on an empty stomach. When patients take NSAIDs alongside blood pressure medications, the drugs can interfere with each other, reducing the effectiveness of treatment for hypertension. The medical landscape for sickle cell pain management is, in short, a minefield.
Some patients have found alternative paths. Ciklavit, a multivitamin derived from the herb Cajanus cajan, and hydroxyurea, a medication that can prevent pain crises, offer ways to reduce dependence on painkillers altogether. Patients using these approaches tend to report better overall health and fewer complications. But access and awareness remain uneven. Perpetua Nnabuenyi, a pharmacist and sickle cell advocate, argues that preventing addiction requires coordinated effort at multiple levels. Patients must adhere to prescribed doses, avoid self-medication, attend regular appointments, and receive education on safe pain management. Families need to watch for early signs of dependence. Healthcare institutions must implement evidence-based protocols, strengthen prescription monitoring, train doctors on responsible opioid prescribing, and integrate psychological support into sickle cell care. Data tracking and timely intervention are essential.
Dr. Paul Anejodo, a registrar in obstetrics and gynecology, offered practical prevention strategies: avoid infections like malaria and respiratory tract infections, stay hydrated, manage stress, live in well-ventilated spaces, and avoid high altitudes. These measures can reduce the frequency and severity of pain crises, lessening the need for opioids in the first place. The challenge ahead is not to deny sickle cell patients the medications they genuinely need, but to build systems that deliver those medications safely, monitor their use carefully, and offer alternatives wherever possible. Without such systems, the pharmacist's patient in Port Harcourt will not be the last to find herself caught between unbearable pain and the risk of addiction to the only relief available.
Notable Quotes
You just want me to suffer. I'm in pain. You can't understand what I'm going through.— Sickle cell patient in Port Harcourt, recounted by pharmacist Chinedum
Preventing drug addiction is a shared responsibility that protects both the health and quality of life of people living with sickle cell disease.— Perpetua Nnabuenyi, pharmacist and sickle cell advocate
The Hearth Conversation Another angle on the story
Why does sickle cell disease create such a specific vulnerability to opioid addiction?
The pain is relentless and severe. A vaso-occlusive crisis can last days. Patients aren't seeking drugs for pleasure—they're seeking escape from something genuinely unbearable. But opioids, especially pentazocine, are designed to create dependence. The brain adapts. After weeks or months of use, the patient's body needs the drug just to feel normal. That's not weakness. That's biology.
But the source mentions "pseudoaddiction" versus real addiction. How do doctors tell the difference?
They often can't, not reliably. A patient who comes back asking for more morphine might be in genuine pain, or might be chasing the high. The problem is that withholding medication from someone in real pain causes real harm. So some doctors err on the side of compassion. Others err on the side of caution. Neither approach is perfect.
What about the alternatives mentioned—hydroxyurea, Ciklavit? Why aren't those the standard?
They work, but they require consistency, access, and time. Hydroxyurea can prevent crises, but it's not a quick fix. Ciklavit is a vitamin supplement. Neither gives you the immediate relief of an injection. And in Nigeria, availability and cost are real barriers. An opioid is fast and it's there.
The pharmacist Chinedum refused to dispense pentazocine without a prescription. Was he being cruel or responsible?
Both, maybe. He was protecting her from addiction. But he was also making her suffer in the moment. She experienced his refusal as abandonment. The real failure is that the system didn't give her better options—didn't give her a doctor who could manage her pain safely, didn't offer her preventive care, didn't address the underlying crisis.
What does "evidence-based pain management protocols" actually mean in practice?
It means hospitals and clinics agree on when to prescribe opioids, at what doses, for how long, and with what monitoring. It means a patient's pain is tracked over time. It means doctors talk to each other so one patient can't doctor-shop. It means psychological support is built in from the start, not added as an afterthought. It means treating the person, not just the pain.
Is there any way to fully solve this without denying sickle cell patients effective pain relief?
Not without addressing prevention—reducing the frequency of crises through hydration, infection control, stress management, altitude avoidance. And not without better access to alternatives like hydroxyurea. But honestly, some level of opioid use will always be necessary for some patients. The goal isn't zero opioids. It's opioids used safely, monitored carefully, and paired with everything else that might reduce the need for them.